Clinical Trial Detail

NCT ID NCT02981628
Title Inotuzumab Ozogamicin in Treating Younger Patients With Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements No
Sponsors Children's Oncology Group
Indications

childhood B-cell acute lymphoblastic leukemia

Therapies

inotuzumab ozogamicin

Age Groups: child adult

No variant requirements are available.